- The FDA has signed off TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) initiation of a Phase 1/2 trial of YH001 in combination with envafolimab and doxorubicin in sarcoma patients, including those who have not received prior therapy.
- The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma.
- Related: TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications.
- Additionally, the safety and efficacy of YH001, envafolimab, and doxorubicin will be assessed in the more prevalent sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
- YH001, an IgG1 antibody against CTLA-4, has shown enhanced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
- Price Action: TCON shares are up 0.50% at $2.02 on the last check Monday.
ExxonMobil’s LNG Leap: Secures 1.2 MTPA Boost From Mexico Pacific Project
Mexico Pacific has inked a third long-term Sales and Purchase Agreement with ExxonMobil LNG Asia Pacific for an additional 1.2 million tonnes per annum of Liquefied Natural Gas from Train 3 of Saguaro Energia project.
